In the first part of this series, we provided an overview of findings along with a general look at drug GMP warning letters over the last six years. If you missed part one, you can find it here.

Here we cover the spread of warning letters outside of the U.S. and review enforcement of OTC manufacturers and contract manufacturers/laboratories. We also look at import alerts associated with warning letters and data integrity deficiencies.

The data presented here for FY2018, ending Sept. 31, 2018, is based on drug GMP warning letters posted by the FDA no later than Jan. 1, 2019.

Following are brief highlights of noteworthy findings and trends, followed by a more detailed analysis:

  • Manufacturers in China received the most warning letters issued to sites in a single country. Firms in China received 24 warning letters, firms in the U.S. received 22 (see Figure 1).
  • The breakaway category of manufacturers in FY2018 that received warning letters are manufacturers of over the counter (OTC), non-prescription drugs. Fifty-three percent of warning letters to drug product manufacturers were issued to OTC manufacturers. This is similar to the seemingly disproportionate enforcement focus that FDA placed on compounding pharmacies and outsourcing facilities several years ago (see Figures 3 and 4).
  • The number of warning letters issued to OTC manufacturers more than doubled between CY2017 and CY2018 from 17 to 39 respectively. More countries, ten vs seven, were associated with these warning letters in CY2018 (see Figures 3 and 4).
  • At least 20 warning letters were issued to firms who were contract manufacturers/laboratories or to firms that did not exercise appropriate controls over their contracted operations. This continues a focus that began last year.
  • Import alerts were associated with 48 of the 73 warning letters issued to sites outside the U.S. in FY2018. Firms in China, India and Korea that received warning letters were the subject of 32 of the 48 import alerts associated with warning letters. China was also in first place here with 21 of the 24 firms who received warning letters being subject to import alerts.
  • The percentage of warning letters that cite deficiencies in data governance/data integrity decreased from the high point of 81% in FY2016 to 60% for firms outside the U.S. in FY2018.  Those issued to U.S. firms decreased from 73% in FY2016 to 45% in FY2018. Data integrity deficiencies are cited in 57% of all warning letters, excluding those issued to compounding pharmacies, down from a high of 79% in FY2016 (see Figures 5 and 6).

[NOTE: No need to click back and forth between blog posts—download the full report instead.]

An Analysis of FDA FY2018 Drug GMP Warning Letters

Figure 1 shows the geographic distribution of warning letters issued outside the U.S. China received the largest number of warning letters issued to a single country in FY2018 and over the six-year period.

2018WL-2-Figure01
Figure 1

India received the next highest number of warning letters, followed at a distance by Europe. Over the past four years the number of warning letters to sites in China has steadily increased, while warning letters issued to sites in India have increased then held steady.

Sites in ‘Asia’ (Japan, China, India, Taiwan and Hong Kong) account for approximately 71% of drug GMP warning letters issued outside the U.S., the same as the percentage over the six year period FY2013 – FY2018.

European countries include the U.K. and are counted together. European-area countries with sites that have received warning letters over the six fiscal years include:

  • Ireland
  • Spain
  • Czech Republic
  • Italy
  • Portugal
  • Denmark
  • Austria
  • Netherlands
  • Germany
  • Hungary
  • the U.K.
  • Switzerland

Figures 2 and 3 show that sites in ‘Asia’ (Japan, China, India, Taiwan and Hong Kong) account for approximately 71% of drug GMP warning letters issued outside the U.S., the same as the percentage over the six-year period FY2013 – FY2018.

Figure 2 and Figure 3

In FY2018 and the six year period FY2013- FY2018 sites in Europe received 12% and 16% of warning letters, respectively. With the Mutual Recognition Agreement between the U.S. and the EU, it will be interesting to see if the number of warning letters to European sites begins to decrease in FY2019. This agreement includes twenty health authorities in the EU effective November 28, 2018 with the remaining EU authorities expected to be added by July 2019.

OTC Manufacturers

CY2018 included a dramatic focus on OTC manufacturers worldwide reminiscent of the focus on compounding pharmacies and outsourcing facilities that began in 2014.

Figures 4 and 5 show the warning letter enforcement data on this group of manufacturers for the last eleven years. The dramatic changes began in CY2017 and increased again in CY2018. The numbers for CY2018 will likely increase beyond those reported here as additional warning letters issued in 2018 are posted in early 2019.

Sites in China and the U.S. each received ten warning letters, sites in South Korea received five and sites in Europe received four. Six additional countries had sites that received either one, two or three warning letters. Both China and South Korea saw more than two-fold increases between CY2017 and 2018. The number of countries increased from seven in CY2017 to ten in CY2018.

2018WL-2-Figure04
2018WL-2-Figure05

Contract Manufacturers and Laboratories

FY2018 warning letters continued to focus on contracted activities, an area of focus that in my opinion will continue into the foreseeable future. At least 20 warning letters mention contracted activities compared to at least 11 last year. Thus, 21% of warning letters issued to firms that were not compounding pharmacies were directly associated with contract manufacturing or testing. Five sites were located each in South Korea, China and the US; Europe had three sites and Australia had two.

Import Alerts Associated with Warning Letters

Seventy-three warning letters were issued regarding sites outside the U.S., and 47 of these had associated import alerts for failure to comply with drug GMPs or refusal of an inspection. So not only did 64% of firms that received warning letters have the expense associated with remediation of the warning letter itself, they are prevented from selling product from these sites in the U.S., excluding FDA-identified medically necessary products.

In many cases this likely provides an economic hardship. Firms in China received 24 warning letters and 21 of these also were placed on import alert. China, India, and Korea taken together, account for 68% of the import alerts associated with warning letters. Each country likely had additional sites that were the subject of import alerts, but these were not associated with warning letters.

Data Integrity Deficiencies in Warning Letters

Figure 6 shows the number of warning letters issued both inside and outside the U.S. that included references to data management and data integrity. This group and analysis excludes those warning letters issued to compounding pharmacies.

Data integrity deficiencies in warning letters continue to identify the predicate rule(s) to which firms did not adhere.

Figure 7 provides a graphic representation of the data. The percentages for both U.S. and OUS warning letters have consistently decreased between FY2016 and FY2018; perhaps we’ve turned the corner here but we still have a long way to go to eliminate this problem.

2018WL-2-Figure06
2018WL-2-Figure06
2018WL Figure 07

Conclusions

Contract manufacturers and their sponsors were a focus again this year, and I would expect that to continue and expand in FY2019. Some sponsors will only take their responsibilities for selection and oversight of contract manufacturers seriously if they suffer an economic impact, such as a contract manufacturer that is subject to a serious enforcement action that results in a delay to product approval or a cessation of manufacture to undertake necessary facility and equipment remediation.  

The breakaway category for warning letters in FY2018 was manufacturers of OTC drug products. This group, on the whole, appears to have failures in fundamental aspects of GMP, including the need for an effective quality unit, testing of incoming materials and components rather than simple reliance on the supplier’s certificate of analysis, testing of product prior to release to the market and failure to have real-time data to support expiry labeling.  

China continues to lead in the country receiving warning letters, as it did in FY2017. This year saw the addition of the Republic of (South) Korea to the countries whose companies received an increasing number of warning letters. I would expect this to continue into FY2019 also.

Where are we heading in 2019? Overall, look for the following trends in warning letter enforcement actions:

  • Continued focus on data integrity and data governance.
  • Continued focus on OTC manufacturers because of the number of individuals using these products and the seemingly poor understanding and compliance with GMPs as shown in this year’s warning letter collection.
  • Contract manufacturers and laboratories and those that contract for their services will see continued attention by the FDA.

In the last post of this series, we will review the interval between inspection and issuance of warning letters, and the interval between inspection and issuance of import alerts. Continue reading here.

[NOTE: No need to click back and forth between blog posts—download the full report instead.]

An Analysis of FDA FY2018 Drug GMP Warning Letters

Download the Special Report

5 GMP Case Studies Report

What You Will Learn from This Report:

In-depth analysis of the findings

Lessons learned

How companies can avoid similar shortcomings.

Download the Special Report

Download your copy of THE FDA INSPECTION LANDSCAPE IN MID-2020 AND A LOOK AT VIRTUAL INSPECTION

In this summary we identify:

  • Trend analysis of FDA inspections through mid-2020
  • Strategies for preparing and hosting virtual inspections
  • New technologies to support remote inspections
Redica Systems Enforcement Analytics

Monitor compliance at your Clinical Investigator sites.

Enter your email address and someone will contact you shortly to get you started.

Redica Systems Enforcement Analytics

Prepare for inspections of Clinical Investigator sites.

Enter your email address and someone will contact you shortly to provide more Clinical Investigator data about your sites.

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to explore enforcement trends. 

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to explore observations and trends. 

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to run your custom report.

Redica Systems Enforcement Analytics

Get help choosing the right CRO.

Enter your email address and someone will contact you shortly to customize your insights.

Redica Systems Enforcement Analytics

Compare two companies of your choice.

Enter your email address and someone will contact you shortly to customize your report.

Download the Special Report

CDMO Comparison opt-in

In this summary we identify:

FY2018-FY2020 GMP data for Lonza & Catalent

Top GMP primary citations

Top FDA 483 observations

Redica Systems Enforcement Analytics

Compare the inspection history of your CDMO sites.

Enter your email address and someone will contact you shortly to customize your report.

Panel Discussion – Remote Audits

Panel Discussion opt in image

Featuring Panelists:
—Barbara W. Unger, Unger Consulting, Inc.
—Jerry Chapman, Redica Systems
—Stephanie Gaulding, Pharmatech Associates

Who Will Benefit?
This session will be valuable to GMP quality, regulatory, compliance, and management personnel in FDA-regulated industries who want to have a conversation on remote audits and get to know what is going on in the industry.

Turning Failure into Success

Presented on Tuesday, April 27, 2021 by Steve Greer, Executive Coach, Genesis Assist, and former Quality Leader, Procter and Gamble

What you will learn:

  • How to use the Leadership SOS Model to transform quality culture
  • How to strengthen quality systems to eliminate human error
  • How to generate ideas on how to set your organization up for success for shareholders, FDA, and staff
Redica Systems Enforcement Analytics

Get Full Access to Redica Enforcement Analytics

Enter your email address and someone will contact you shortly to answer all of your questions and get you started.

Quality Management Systems for Small Pharma and Biotech Firms

Webinar: QMS for Small Pharma and Biotech Firms

Presented by Fenton Fong, Founder, Managing Director, & Principal at xCellarate

Get instant access to the webinar video and slides.

What you will learn:

  • Common challenges small pharma firms face when developing a QMS
    Recent enforcement trends involving the Quality Unit
    Impact of the COVID-19 pandemic

Download the Special Report

APAC ad

In this summary we identify:

GMP data from FY2017 to FY2020 for the Asia-Pacific region

Top 3 GMP primary and secondary citations

Top 3 483 observations

Download the Special Report

An Analysis Of MHRA’s Latest Annual GMP Inspection Deficiencies Report

In this summary we identify:

  • Data from 2019 UK MHRA Inspections
  • Trends from 2015, 2016, 2018, and 2019 inspections
  • Conclusions drawn from an analysis of drug inspection data

Experience the Power of Redica Systems

Redica_Vert_Periwinkle_RGB_Large

SEARCH Find the inspection records you want by inspector’s name, company name, site, city, country, etc.

WARNING LETTERS Easily search the largest database of FDA Warning Letters by date, company, FDA office, or subject

SITES Quickly assess inspection records including dates and inspectors across all of your sites

INSPECTIONS Complete list of FDA inspections by date, company, category, and country

Get Complete Access to the Redica Systems Platform

Please submit your email address and one of our team members will contact you shortly to answer all of your questions and get you started with the new Enforcement Analytics platform.

Redica Systems Enforcement Analytics

Compare the enforcement history of your CDMOs.

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Evaluate Your CDMOs

Enter your email address and someone will contact you shortly to customize your report.

Experience the Power of Redica Systems

Redica Systems Expert Jerry Chapman to Present at SQA Annual Meeting

Index Information Redica consolidates regulatory data in real-time on the single largest database for quality, safety, and compliance intelligence.

Strengthen Datasets Redica machine intelligence algorithms identify and triage risk signals to derive meaning from vast amounts of private and public data.

Analyze & Interpret Patterns Redica instantly models the customer-specific regulatory risks, trends, and opportunities that stand to fundamentally change compliance operations.

Redica Systems Enforcement Analytics

Save your team valuable time when using External Monitoring.

Enter your email address and someone will contact you shortly. 

Download the 510(k) Sample

What You Will Learn from This Sample:

See how a 510(k) submission is structured

Find out what information to include

Review correspondence between sponsor and FDA

Redica Systems Enforcement Analytics

Unlimited Access to Reports and Data

Enter your email address and someone will contact you shortly.

Download the Special Report

5 GMP Case Studies Report

What You Will Learn from This Report:

The first countrywide import alert issued by FDA

An inadequate deviation investigation

An inadequate product specifications and a product recall

Process validation issues at a CMO

A different perspective on process validation and the culpability of the quality unit

 

A.I. for Quality and Compliance Teams

August 3 webinar

Presented by Redica Systems Senior GMP Quality Expert Jerry Chapman

What you will learn:

  • A basic understanding of data sources, machine learning, NLP, and A.I. tools
  • Building and applying Expert Models
  • Two case studies, one on sterile manufacturing/503B and one on data integrity

Get the scoop on recent data integrity 483 observations!

  • FY 2020 Data Integrity 483 Observations
  • Data Integrity Observations for Human Drugs
  • Observations Falling Under GMP
  •  

Human Factors – Compliance and Applications

June webinar

Presented by Alison Sathe, Founder, Regulatory Mark & Valerie Fenster, Director of Insights and  Human Factors, Kaleidoscope Innovation 

What you will learn:

  • Human factors strategies from simple drug products to complex surgical devices
  • Primary and secondary labeling development and evaluation for usability
  • Human factors activities from product development to post-market
  • International strategies: expectations for human factors in regulatory submissions in international markets

Experience the Power of Redica Systems

Redica Systems Enforcement Analytics

Let us know who you are and we’ll be in touch to answer all of your questions and get you started.

Redica Systems Enforcement Analytics

Keep up with the latest Regulatory Developments on Clinical Trials

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Save time and Resources when using External Monitoring.

Enter your email address and someone will contact you shortly. 

Experience the Power of Redica Systems

Complete the form and one of our experts will reach out to you to schedule a demo and answer questions about our subscription options.

INDEX INFORMATION  Redica consolidates regulatory data in real-time on the single largest database for quality, safety, and compliance intelligence.

STRENGTHEN DATASETS Redica machine intelligence algorithms identify and triage risk signals to derive meaning from vast amounts of private and public data.

ANALYZE & INTERPRET PATTERNS Redica instantly models the customer-specific regulatory risks, trends, and opportunities that stand to fundamentally change compliance operations.

Redica Systems Enforcement Analytics

Get immediate access to the news that matters to your sites.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

See how we can help you eliminate yet another spreadsheet.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Stay ahead of changing regulations.

Enter your email address and someone will contact you shortly to get the data and analysis you need.

Redica Systems Enforcement Analytics

Upgrade your CDMO monitoring strategy.

Enter your email address and someone will contact you shortly to get the data and analysis you need.

Redica Systems Enforcement Analytics

Upgrade your CDMO management strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need.

Experience the Power of Redica Systems

Redica Systems Enforcement Analytics

Sign up for your FREE account today and get instant access to Enforcement Analytics.

Redica Systems Enforcement Analytics

Upgrade your inspection strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need.

Redica Systems Enforcement Analytics

Upgrade your inspection strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need to prepare for your next inspection.

Discover the power of the most comprehensive database of 483s in existence.

Our database of over 20,000 483s is retyped and tagged, making it easy to create an Observation Report in seconds.

Eliminate days of work and get your FREE personalized 483 Observation Report.